Table 4.
Cumulative medication use by Hispanic lupus patients residing in the USA and Mexico
| Feature | Texas, n = 94 | Mexico, n = 70 | P-value* |
|---|---|---|---|
| HCQ or chloroquine, % | 83 | 67 | 0.0903 |
| Glucocorticoids, % | 95 | 94 | |
| Intravenous glucocorticoids, % | 20 | 21 | |
| Glucocorticoids highest dose, mean ± s.d. | 46 ± 26.8 | 50.2 ± 26.2 | <0.0001 |
| Glucocorticoids average dose, mean ± s.d. | 17.9 ± 15.6 | 13.7 ± 12.3 | 0.0237 |
| Intravenous cyclophosphamide, % | 10 | 3 | 0.0750 |
| AZA, % | 19 | 73 | <0.0001 |
| MTX, % | 16 | 24 | |
| LEF, % | 0 | 1 | |
| Mycophenolate mofetil, % | 10 | 3 | 0.0880 |
| Cyclosporin, % | 3 | 0 | |
| Aspirin, % | 14 | 63 | <0.0001 |
| NSAIDs, % | 55 | 60 | |
| ACE inhibitors, % | 43 | 47 | <0.0001 |
| Anti-depressants, % | 22 | 19 | |
| Statins, % | 7 | 19 | 0.0113 |
| Bisphosphonates, % | 11 | 0 | |
| OCPs | 19 | 28 |
*Only P-values <0.10 are shown; all comparisons are adjusted for age at the last visit.